Melatonin increases survival and inhibits oxidative and amyloid pathology in a transgenic model of Alzheimer's disease.

Journal Article (Journal Article)

Increased levels of a 40-42 amino-acid peptide called the amyloid beta protein (A beta) and evidence of oxidative damage are early neuropathological markers of Alzheimer's disease (AD). Previous investigations have demonstrated that melatonin is decreased during the aging process and that patients with AD have more profound reductions of this hormone. It has also been recently shown that melatonin protects neuronal cells from A beta-mediated oxidative damage and inhibits the formation of amyloid fibrils in vitro. However, a direct relationship between melatonin and the biochemical pathology of AD had not been demonstrated. We used a transgenic mouse model of Alzheimer's amyloidosis and monitored over time the effects of administering melatonin on brain levels of A beta, abnormal protein nitration, and survival of the mice. We report here that administration of melatonin partially inhibited the expected time-dependent elevation of beta-amyloid, reduced abnormal nitration of proteins, and increased survival in the treated transgenic mice. These findings may bear relevance to the pathogenesis and therapy of AD.

Full Text

Duke Authors

Cited Authors

  • Matsubara, E; Bryant-Thomas, T; Pacheco Quinto, J; Henry, TL; Poeggeler, B; Herbert, D; Cruz-Sanchez, F; Chyan, Y-J; Smith, MA; Perry, G; Shoji, M; Abe, K; Leone, A; Grundke-Ikbal, I; Wilson, GL; Ghiso, J; Williams, C; Refolo, LM; Pappolla, MA; Chain, DG; Neria, E

Published Date

  • June 2003

Published In

Volume / Issue

  • 85 / 5

Start / End Page

  • 1101 - 1108

PubMed ID

  • 12753069

Electronic International Standard Serial Number (EISSN)

  • 1471-4159

International Standard Serial Number (ISSN)

  • 0022-3042

Digital Object Identifier (DOI)

  • 10.1046/j.1471-4159.2003.01654.x


  • eng